{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:39:11Z","timestamp":1789706351116,"version":"4.0.1"},"reference-count":29,"publisher":"BMJ","issue":"6","funder":[{"name":"Gruppo Italiano Mesotelioma onlus"},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Occup Environ Med"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1136\/oemed-2016-104024","type":"journal-article","created":{"date-parts":[[2017,3,26]],"date-time":"2017-03-26T00:10:23Z","timestamp":1490487023000},"page":"457-464","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals"],"prefix":"10.1136","volume":"74","author":[{"given":"Chiara","family":"De Santi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla","family":"Pucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bonotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Melaiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Cipollini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Vymetalkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5444-354X","authenticated-orcid":false,"given":"Elisa","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Paolicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alda","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lepori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Dell\u2019Anno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pell\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Vodicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Mutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy","family":"Foddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Cristaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Gemignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,3,25]]},"reference":[{"key":"key-10.1136\/oemed-2016-104024-1","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-03-0801","article-title":"Mesothelin: a new target for immunotherapy","volume":"10","author":"Hassan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"key-10.1136\/oemed-2016-104024-2","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol Cell Biol"},{"key":"key-10.1136\/oemed-2016-104024-3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur J Cancer"},{"key":"key-10.1136\/oemed-2016-104024-4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ctrv.2015.05.001","article-title":"The established and future biomarkers of malignant pleural mesothelioma","volume":"41","author":"Panou","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"key-10.1136\/oemed-2016-104024-5","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"key-10.1136\/oemed-2016-104024-6","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung Cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key-10.1136\/oemed-2016-104024-7","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1158\/1078-0432.CCR-10-2275","article-title":"Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers","volume":"16","author":"Hassan","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key-10.1136\/oemed-2016-104024-8","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1002\/cncr.28875","article-title":"Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer\u00a0antigen 125","volume":"120","author":"Hassan","year":"2014","journal-title":"Cancer"},{"key":"key-10.1136\/oemed-2016-104024-9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.athoracsur.2007.07.042","article-title":"Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions","volume":"85","author":"Pass","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"key-10.1136\/oemed-2016-104024-10","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3892\/mco.2013.175","article-title":"Combined serum mesothelin and carcinoembryonic antigen measurement in the diagnosis of malignant mesothelioma","volume":"1","author":"Fukuoka","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"key-10.1136\/oemed-2016-104024-11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004145","article-title":"Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis","volume":"4","author":"Cui","year":"2014","journal-title":"BMJ Open"},{"key":"key-10.1136\/oemed-2016-104024-12","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1373\/clinchem.2008.121913","article-title":"Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum","volume":"55","author":"Hollevoet","year":"2009","journal-title":"Clin Chem"},{"key":"key-10.1136\/oemed-2016-104024-13","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1515\/CCLM.2010.165","article-title":"Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population","volume":"48","author":"Park","year":"2010","journal-title":"Clin Chem Lab Med"},{"key":"key-10.1136\/oemed-2016-104024-14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s12032-012-0422-6","article-title":"Individual predictors of increased serum mesothelin in asbestos-exposed workers","volume":"30","author":"Filiberti","year":"2013","journal-title":"Med Oncol"},{"key":"key-10.1136\/oemed-2016-104024-15","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/JTO.0000000000000322","article-title":"A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people","volume":"9","author":"Garritano","year":"2014","journal-title":"J Thorac Oncol"},{"key":"key-10.1136\/oemed-2016-104024-16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5301\/JBM.2011.8332","article-title":"Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels","volume":"26","author":"Cristaudo","year":"2011","journal-title":"Int J Biol Markers"},{"key":"key-10.1136\/oemed-2016-104024-17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ng.2653","article-title":"The Genotype-Tissue Expression (GTEx) project","volume":"45","author":"Lonsdale","year":"2013","journal-title":"Nat Genet"},{"key":"key-10.1136\/oemed-2016-104024-18","first-page":"979","article-title":"Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma","volume":"134","author":"Ke","year":"1989","journal-title":"Am J Pathol"},{"key":"key-10.1136\/oemed-2016-104024-19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/oem.2009.049205","article-title":"Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein","volume":"67","author":"Cristaudo","year":"2010","journal-title":"Occup Environ Med"},{"key":"key-10.1136\/oemed-2016-104024-20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.18388\/abp.2013_2000","article-title":"Matrix metalloproteinase-2 C(-1306)T promoter polymorphism and breast cancer risk in the saudi population","volume":"60","author":"Saeed","year":"2013","journal-title":"Acta Biochim Pol"},{"key":"key-10.1136\/oemed-2016-104024-21","article-title":"A novel functional TagSNP Rs7560488 in the DNMT3A1 promoter is associated with susceptibility to gastric cancer by modulating promoter activity","volume":"9","author":"Wu","year":"2014","journal-title":"PLoS One"},{"key":"key-10.1136\/oemed-2016-104024-22","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.7314\/APJCP.2015.16.7.2707","article-title":"Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development","volume":"16","author":"Cingeetham","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"key-10.1136\/oemed-2016-104024-23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1373\/clinchem.2007.102400","article-title":"Association between ESR2 genetic variants and risk of myocardial infarction","volume":"54","author":"Domingues-Montanari","year":"2008","journal-title":"Clin Chem"},{"key":"key-10.1136\/oemed-2016-104024-24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1534734613493289","article-title":"A functional single nucleotide polymorphism -1562C>T in the matrix metalloproteinase-9 promoter is associated with type 2 diabetes and diabetic foot ulcers","volume":"12","author":"Singh","year":"2013","journal-title":"Int J Low Extrem Wounds"},{"key":"key-10.1136\/oemed-2016-104024-25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.gene.2013.09.088","article-title":"The polymorphism (-600 C>A) of CpG methylation site at the promoter region of CYP17A1 and its association of male infertility and testosterone levels","volume":"534","author":"Park","year":"2014","journal-title":"Gene"},{"key":"key-10.1136\/oemed-2016-104024-26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000445358","article-title":"A CpG-SNP located within the ARPC3 gene promoter is associated with hypertriglyceridemia in severely obese patients","volume":"68","author":"de Toro-Mart\u00edn","year":"2016","journal-title":"Ann Nutr Metab"},{"key":"key-10.1136\/oemed-2016-104024-27","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.humpath.2010.03.002","article-title":"Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter","volume":"41","author":"Tan","year":"2010","journal-title":"Hum Pathol"},{"key":"key-10.1136\/oemed-2016-104024-28","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4161\/epi.6.8.16074","article-title":"The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma","volume":"6","author":"Nelson","year":"2011","journal-title":"Epigenetics"},{"key":"key-10.1136\/oemed-2016-104024-29","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1158\/1055-9965.EPI-08-0374","article-title":"Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer","volume":"17","author":"Cramer","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Occupational and Environmental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/oemed-2016-104024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T07:33:32Z","timestamp":1601105612000},"score":1,"resource":{"primary":{"URL":"https:\/\/oem.bmj.com\/lookup\/doi\/10.1136\/oemed-2016-104024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,25]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,5,24]]},"published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1136\/oemed-2016-104024"],"URL":"https:\/\/doi.org\/10.1136\/oemed-2016-104024","relation":{},"ISSN":["1351-0711","1470-7926"],"issn-type":[{"value":"1351-0711","type":"print"},{"value":"1470-7926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,25]]}}}